Vasella wins chairman role at Alcon

Novartis Chairman Daniel Vasella (photo) was elected to the additional position of board chairman of Alcon, a move that further asserts Novartis's control of the eye-care company as it seeks to buy the 23 percent it doesn't already own. Report

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.